Uni Pharma Co Ltd

Chart & Performance

D1W1MN

P/E

—

P/S

4.66

EPS

—

Div Yield, %

—

Shrs. gr., 5y

0.17%

Rev. gr., 5y

-8.60%

Revenues

88m

-5.36%

Net income

-41m

L+63.36%

CFO

-37m

L+156.23%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Profile

UniPharma Co., Ltd. is a Taiwanese enterprise specializing in the distribution of pharmaceuticals, medical apparatus, and diagnostic kits. Its diagnostic portfolio encompasses various medical disciplines, including oncology, gynecology, orthopedics, neurology, anesthesiology, and cardiology. The company's offerings feature products such as Adept reduction solution, anesthetic injections (including bain, esmolol HCI, and naloxone), the Elisa DR-70 test for in-vitro tumor detection, and Fomeject antidote injections. Furthermore, UniPharma extends its services to include drug development, research and development, clinical studies, and marketing. Its client base includes major medical centers, regional hospitals, and local clinics. Founded in 1998, UniPharma is headquartered in Taipei, Taiwan.

URL

http://www.uni-pharma.com/

IPO date

Aug 18, 2017

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title TWD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY
Title TWD in thousands, except ratios and share amounts	2025‑12	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT